Comparative safety evaluation of selective androgen receptor modulators and anabolic androgenic steroids

Bibliography

• Keller ET, Ershler WB, Chang C. The androgen receptor: a mediator of diverse responses. Front Biosci 1996;1:d59–71
   PubMedGoogle Scholar
• Bagatell CJ, Bremner WJ. Androgens in men—uses and abuses. N Engl J Med 1996;334:707–14
   PubMed Web of Science ®Google Scholar
• Neto WK, Gama EF, Rocha LY, et al. Effects of testosterone on lean mass gain in elderly men: systematic review with meta-analysis of controlled and randomized studies. Age (Dordr) 2015;37:9742
   PubMed Web of Science ®Google Scholar
• Darke S, Torok M, Duflou J. Sudden or unnatural deaths involving anabolic-androgenic steroids. J Forensic Sci 2014;59:1025–8
   PubMed Web of Science ®Google Scholar
• Dalton JT, Mukherjee A, Zhu Z, et al. Discovery of nonsteroidal androgens. Biochem Biophys Res Commun 1998;244:1–4
   PubMed Web of Science ®Google Scholar
• Edwards JP, West SJ, Pooley CL, et al. New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone. Bioorg Med Chem Lett 1998;8:745–50
   PubMed Web of Science ®Google Scholar
• Negro-Vilar A. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab 1999;84:3459–62
   PubMed Web of Science ®Google Scholar
• Ward HW. Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J 1973;1:13–14
   PubMed Web of Science ®Google Scholar
• Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr Rev 2002;23:175–200
   PubMed Web of Science ®Google Scholar
• Narayanan R, Mohler ML, Bohl CE, et al. Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal 2008;6:e010
   PubMedGoogle Scholar
• Zhang X, Sui Z. Deciphering the selective androgen receptor modulators paradigm. Expert Opin Drug Discov 2013;8:191–218
   PubMed Web of Science ®Google Scholar
• Gao W, Dalton JT. Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discov Today 2007;12:241–8
   PubMed Web of Science ®Google Scholar
• Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther 2001;23:1355–90
   PubMed Web of Science ®Google Scholar
• Wang YJ, Zhan JK, Huang W, et al. Effects of low-dose testosterone undecanoate treatment on bone mineral density and bone turnover markers in elderly male osteoporosis with low serum testosterone. Int J Endocrinol 2013;2013:570413
   PubMedGoogle Scholar
• Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol 2008;154:502–21
   PubMed Web of Science ®Google Scholar
• Gooren LJ. A ten-year safety study of the oral androgen testosterone undecanoate. J Androl 1994;15:212–15
   PubMed Web of Science ®Google Scholar
• Nieschlag E, Swerdloff R, Behre HM, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2005;8:56–8
   PubMedGoogle Scholar
• Nieschlag E, Büchter D, Von Eckardstein S, et al. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clin Endocrinol (Oxf) 1999;51:757–63
   PubMed Web of Science ®Google Scholar
• Busardò FP, Frati P, Sanzo MD, et al. The Impact of Nandrolone Decanoate on the Central Nervous System. Curr Neuropharmacol 2015;13:122–31
   PubMed Web of Science ®Google Scholar
• Mora C, Macía ML, García J, et al. Effect of nandrolone decanoate on the lipid profile of male peritoneal dialysis patients. Perit Dial Int 2001;21:611–14
   PubMed Web of Science ®Google Scholar
• Ghorbanihaghjo A, Argani H, Rohbaninoubar M, et al. Effect of Nandrolone Decanoate on serum lipoprotein (a) and its isoforms in hemodialysis patients. Lipids Health Dis 2004;3:16
   PubMedGoogle Scholar
• Gooren LJ. Advances in testosterone replacement therapy. Front Horm Res 2009;37:32–51
   PubMed Web of Science ®Google Scholar
• Layton JB, Meier CR, Sharpless JL, et al. Comparative Safety of Testosterone Dosage Forms. JAMA Intern Med 2015;175:1187–96
   PubMed Web of Science ®Google Scholar
• Pope HGJr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev 2014;35:341–75
   PubMed Web of Science ®Google Scholar
• Ladosky W, Kesikowski WM. Testicular development in rats treated with several steroids shortly after birth. J Reprod Fertil 1969;19:247–54
   PubMedGoogle Scholar
• Blasberg ME, Langan CJ, Clark AS. The effects of 17 alpha-methyltestosterone, methandrostenolone, and nandrolone decanoate on the rat estrous cycle. Physiol Behav 1997;61:265–72
   PubMed Web of Science ®Google Scholar
• Clark AS, Kelton MC, Whitney AC. Chronic administration of anabolic steroids disrupts pubertal onset and estrous cyclicity in rats. Biol Reprod 2003;68:465–71
   PubMed Web of Science ®Google Scholar
• Nesterin MF, Budik VM, Narodetskaia RV, et al. Effect of methandrostenolone on liver morphology and enzymatic activity. Farmakol Toksikol 1980;43:597–601
   PubMedGoogle Scholar
• Ruzicka L, Goldberg MW, Rosenberg HR, Sexualhormone X. Herstellung des 17-Methyltestosteron und anderer Androsten und Androstanderivate, Ausammenhange wwischen chemischer Konstitution und mannlicher Hormonwirkung. Helv Chim Acta 1935;18:1487–98
   Google Scholar
• Foss GL. Oral Methyl Testosterone. Br Med J 1939;2:11–28
   PubMedGoogle Scholar
• Heywood R, Chesterman H, Ball SA, et al. Toxicity of methyltestosterone in the beagle dog. Toxicology 1977;7:357–65
   PubMed Web of Science ®Google Scholar
• Taylor W, Snowball S, Lesna M. The effects of long-term administration of methyltestosterone on the development of liver lesions in BALB/c mice. J Pathol 1984;143:211–18
   PubMed Web of Science ®Google Scholar
• Hild SA, Attardi BJ, Koduri S, et al. Effects of synthetic androgens on liver function using the rabbit as a model. J Androl 2010;31:472–81
   PubMed Web of Science ®Google Scholar
• Kawashima K, Nakaura S, Nagao S, et al. Virilizing effect of methyltestosterone on female descendants in the rat. Endocrinol Jpn 1978;25:1–6
   PubMedGoogle Scholar
• Shirai T, Sakata T, Fukushima S, et al. Rat prostate as one of the target organs for 3,2′-dimethyl-4-aminobiphenyl-induced carcinogenesis: effects of dietary ethinyl estradiol and methyltestosterone. Jpn J Cancer Res 1985;76:803–8
   PubMedGoogle Scholar
• Pavlatos AM, Fultz O, Monberg MJ, et al. Review of oxymetholone: a 17alpha-alkylated anabolic-androgenic steroid. Clin Ther 2001;23:789–801
   PubMed Web of Science ®Google Scholar
• Welder AA, Robertson JW, Melchert RB. Toxic effects of anabolic-androgenic steroids in primary rat hepatic cell cultures. J Pharmacol Toxicol Methods 1995;33:187–95
   PubMed Web of Science ®Google Scholar
• Boris A, Trmal T, Nelson EWJr. Anti-ovulatory effects of some androgenic-myotrophic steroids in the pubertal rat. Contraception 1972;5:489–95
   PubMed Web of Science ®Google Scholar
• National Toxicology Program (NTP). NTP Toxicology and Carcinogenesis Studies of Oxymetholone (CAS NO. 434-07-1) in F344/N Rats and Toxicology Studies of Oxymetholone in B6C3F1 Mice (Gavage Studies). Natl Toxicol Program Tech Rep Ser 1999;485:1–233
   PubMedGoogle Scholar
• Holden HE, Stoll RE, Blanchard KT. Oxymetholone: II. Evaluation in the Tg-AC transgenic mouse model for detection of carcinogens. Toxicol Pathol 1999;27:507–12
   PubMed Web of Science ®Google Scholar
• Stoll RE, Holden HE, Barthel CH, et al. Oxymetholone: III. Evaluation in the p53+/- transgenic mouse model. Toxicol Pathol 1999;27:513–18
   PubMed Web of Science ®Google Scholar
• Boada LD, Zumbado M, Torres S, et al. Evaluation of acute and chronic hepatotoxic effects exerted by anabolic-androgenic steroid stanozolol in adult male rats. Arch Toxicol 1999;73:465–72
   PubMed Web of Science ®Google Scholar
• Harkin KR, Cowan LA, Andrews GA, et al. Hepatotoxicity of stanozolol in cats. J Am Vet Med Assoc 2000;217:681–4
   PubMed Web of Science ®Google Scholar
• Whitney AC, Clark AS. Effects of acute stanozolol treatment on puberty in female rats. Biol Reprod 2001;64:1460–5
   PubMed Web of Science ®Google Scholar
• Ghia M, Mereto E. Assay of stanozolol for tumor initiating and promoting activity in two rat liver foci bioassays. Cancer Lett 1992;63:203–9
   PubMed Web of Science ®Google Scholar
• Fogelberg M, Björkhem I, Diczfalusy U, et al. Stanozolol and experimental atherosclerosis: atherosclerotic development and blood lipids during anabolic steroid therapy of New Zealand white rabbits. Scand J Clin Lab Invest 1990;50:693–6
   PubMed Web of Science ®Google Scholar
• Shufelt CL, Braunstein GD. Safety of testosterone use in women. Maturitas 2009;63:63–6
   PubMed Web of Science ®Google Scholar
• van Amsterdam J, Opperhuizen A, Hartgens F. Adverse health effects of anabolic-androgenic steroids. Regul Toxicol Pharmacol 2010;57:117–23
   PubMed Web of Science ®Google Scholar
• Martins RA, Gomes GA, Aguiar OJr, et al. Chromosome damage and cytotoxicity in oral mucosa cells after 2 months of exposure to anabolic steroids (decadurabolin and winstrol) in weight lifting. Steroids 2010;75:952–5
   PubMed Web of Science ®Google Scholar
• Santamarina RD, Besocke AG, Romano LM, et al. Ischemic stroke related to anabolic abuse. Clin Neuropharmacol 2008;31:80–5
   PubMed Web of Science ®Google Scholar
• Socas L, Zumbado M, Pérez-Luzardo O, et al. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. Br J Sports Med 2005;39:e27
   PubMed Web of Science ®Google Scholar
• Stimac D, Milić S, Dintinjana RD, et al. Androgenic/Anabolic steroid-induced toxic hepatitis. J Clin Gastroenterol 2002;35:350–2
   PubMed Web of Science ®Google Scholar
• Modlinski R, Fields KB. The effect of anabolic steroids on the gastrointestinal system, kidneys, and adrenal glands. Curr Sports Med Rep 2006;5:104–9
   PubMedGoogle Scholar
• van der Vies J. Pharmacokinetics of anabolic steroids. Wien Med Wochenschr 1993;143:366–8
   PubMedGoogle Scholar
• Allender S, Peto V, Scarborough P, et al. Coronary Heart Disease Statistics. British Heart Foundation 2008
   Google Scholar
• Haring R, John U, Völzke H, et al. Low testosterone concentrations in men contribute to the gender gap in cardiovascular morbidity and mortality. Gend Med 2012;9:557–68
   PubMed Web of Science ®Google Scholar
• Thompson PD, Cullinane EM, Sady SP, et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 1989;261:1165–8
   PubMed Web of Science ®Google Scholar
• Lippi G, Guidi G, Ruzzenente O, et al. Effects of nandrolone decanoate (Decadurabolin) on serum Lp(a), lipids and lipoproteins in women with postmenopausal osteoporosis. Scand J Clin Lab Invest 1997;57:507–11
   PubMed Web of Science ®Google Scholar
• Hartgens F, Rietjens G, Keizer HA, et al. Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). Br J Sports Med 2004;38:253–9
   PubMed Web of Science ®Google Scholar
• McNutt RA, Ferenchick GS, Kirlin PC, et al. Acute myocardial infarction in a 22-year-old world class weight lifter using anabolic steroids. Am J Cardiol 1988;62:164
   PubMed Web of Science ®Google Scholar
• Nieminen MS, Rämö MP, Viitasalo M, et al. Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. Eur Heart J 1996;17:1576–83
   PubMed Web of Science ®Google Scholar
• Severo CB, Ribeiro JP, Umpierre D, et al. Increased atherothrombotic markers and endothelial dysfunction in steroid users. Eur J Prev Cardiol 2013;20:195–201
   Web of Science ®Google Scholar
• Maclaran K, Panay N. The safety of postmenopausal testosterone therapy. Womens Health (Lond Engl) 2012;8:263–75
   PubMedGoogle Scholar
• Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008;93:68–75
   PubMed Web of Science ®Google Scholar
• Vikan T, Johnsen SH, Schirmer H, et al. Endogenous testosterone and the prospective association with carotid atherosclerosis in men: the Tromsø study. Eur J Epidemiol 2009;24:289–95
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Miner MM, Caliber M, et al. Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin Proc 2015;90:224–51
   PubMed Web of Science ®Google Scholar
• Frati P, Busardò FP, Cipolloni L, et al. Anabolic Androgenic Steroid (AAS) Related Deaths: Autoptic, Histopathological and Toxicological Findings. Curr Neuropharmacol 2015;13:146–59
   PubMed Web of Science ®Google Scholar
• Kanayama GI, Hudson JI, Pope HG. Jr. Illicit anabolic-androgenic steroid use. Horm Behav 2010;58:111–21
   PubMed Web of Science ®Google Scholar
• McKenna NJ, Lanz RB, O’Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999;20:321–44
   PubMed Web of Science ®Google Scholar
• He Y, Yin D, Perera M, et al. Novel nonsteroidal ligands with high binding affinity and potent functional activity for the androgen receptor. Eur J Med Chem 2002;37:619–34
   PubMed Web of Science ®Google Scholar
• Jones JO. Improving selective androgen receptor modulator discovery and preclinical evaluation. Expert Opin Drug Discov 2009;4:981–93
   PubMed Web of Science ®Google Scholar
• Bebermeier JH, Brooks JD, DePrimo SE, et al. Cell-line and tissue-specific signatures of androgen receptor-coregulator transcription. J Mol Med (Berl) 2006;84:919–31
   PubMed Web of Science ®Google Scholar
• Gao W, Dalton JT. Ockham’s razor and selective androgen receptor modulators (SARMs): are we overlooking the role of 5alpha-reductase? Mol Interv 2007;7:10–13
   PubMed Web of Science ®Google Scholar
• Tsugaya M, Harada N, Tozawa K, et al. Aromatase mRNA levels in benign prostatic hyperplasia and prostate cancer. Int J Urol 1996;3:292–6
   PubMedGoogle Scholar
• Srinath R, Dobs A. Enobosarm (GTx-024, S-22): a potential treatment for cachexia. Future Oncol 2014;10:187–94
   PubMed Web of Science ®Google Scholar
• Basaria S, Collins L, Dillon EL, et al. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci 2013;68:87–95
   PubMed Web of Science ®Google Scholar
• Marcantonio EE, Witter RE, Ding Y, et al. A 12-week pharmacokinetic and pharmacodynamic study of two selective androgen receptor modulators (SARMs) in postmenopausal subjects. Enodrine Reviews Supplement 1 2010;31:S872
   Google Scholar
• Papanicolaou DA, Ather SN, Zhu H, et al. A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia. J Nutr Health Aging 2013;17:533–43
   PubMed Web of Science ®Google Scholar
• DART therapeutics develops drug candidate for Duchenne muscular dystrophy. DART Therapeutics Inc. 2013. Available from: www.reuters.com/article/2013/03/20/ma-dart-theraputics-idUSnPnNE79920+160+PRN20130320
   Google Scholar
• Safety, tolerability, pharmacokinetics, and pharmacodynamics study of GSK2881078 in single and repeat doses (NCT02045940). 2014. Available from: www.clinicaltrials.gov
   Google Scholar
• Dalton JT, Taylor RP, Mohler ML, et al. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer. Curr Opin Support Palliat Care 2013;7:345–51
   PubMed Web of Science ®Google Scholar
• Dalton JT, Barnette KG, Bohl CE, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle 2011;2:153–61
   PubMed Web of Science ®Google Scholar
• Dobs AS, Boccia RV, Croot CC, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol 2013;14:335–45
   PubMed Web of Science ®Google Scholar
• Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011;364:127–35
   PubMed Web of Science ®Google Scholar
• Rader DJ, Alexander ET, Weibel GL, et al. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res 2009;50(Suppl):S189–94
   PubMed Web of Science ®Google Scholar
• Rubinow KB, Vaisar T, Tang C, et al. Testosterone replacement in hypogonadal men alters the HDL proteome but not HDL cholesterol efflux capacity. J Lipid Res 2012;53:1376–83
   PubMed Web of Science ®Google Scholar
• Langer C, Gansz B, Goepfert C, et al. Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochem Biophys Res Commun 2002;296:1051–7
   PubMed Web of Science ®Google Scholar
• Ueda Y, Gong E, Royer L, et al. Relationship between expression levels and atherogenesis in scavenger receptor class B, type I transgenics. J Biol Chem 2000;275:20368–73
   PubMed Web of Science ®Google Scholar
• Isbarn H, Pinthus JH, Marks LS, et al. Testosterone and prostate cancer: revisiting old paradigms. Eur Urol 2009;56:48–56
   PubMed Web of Science ®Google Scholar
• Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005;60:1451–7
   PubMed Web of Science ®Google Scholar
• Fernández-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95:2560–75
   PubMed Web of Science ®Google Scholar
• Goldenberg SL, Koupparis A, Robinson ME. Differing levels of testosterone and the prostate: a physiological interplay. Nat Rev Urol 2011;8:365–77
   PubMed Web of Science ®Google Scholar
• Izumi K, Mizokami A, Lin WJ, et al. Androgen Receptor Roles in the Development of Benign Prostate Hyperplasia (BPH). Am J Pathol 2013;182:1942–9
   PubMed Web of Science ®Google Scholar
• Allan G, Sbriscia T, Linton O, et al. A selective androgen receptor modulator with minimal prostate hypertrophic activity restores lean body mass in aged orchidectomized male rats. J Steroid Biochem Mol Biol 2008;110:207–13
   PubMed Web of Science ®Google Scholar
• Vajda EG, López FJ, Rix P, et al. Pharmacokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quinolin-7(6H)-one], an orally available nonsteroidal-selective androgen receptor modulator. J Pharmacol Exp Ther 2009;328:663–70
   PubMed Web of Science ®Google Scholar
• Narayanan R, Ahn S, Cheney MD, et al. Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling. PLoS One 2014;9:e103202
   PubMed Web of Science ®Google Scholar
• Shimoji N, Imaida K, Hasegawa R, et al. Enhancing effect of oxymetholone, an anabolic steroid, on development of liver cell foci in rats initiated with N-diethylnitrosamine. Cancer Lett 1990;49:165–8
   PubMed Web of Science ®Google Scholar